We are live on ! Find out more
XLO icon

Xilio Therapeutics

30 hedge funds and large institutions have $33.5M invested in Xilio Therapeutics in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.05% less ownership

Funds ownership: 4.16%4.11% (-0.05%)

6% less funds holding

Funds holding: 3230 (-2)

20% less capital invested

Capital invested by funds: $41.9M → $33.5M (-$8.46M)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
30
Holders Change
-2
Holders Change %
-6.25%
% of All Funds
0.48%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
1
Increased
5
Reduced
7
Closed
3
Calls
Puts
Net Calls
Net Calls Change

XLO Hedge Fund Activity: Q3 2023 in Review

30 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Xilio Therapeutics (XLO) for Q3 2023, worth a combined $33.5M — down 20% from $41.9M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of XLO and 1 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 5 added.

The largest buyer was Dimensional Fund Advisors, adding an estimated $22.8K. The largest seller was Octagon Capital Advisors, cutting an estimated $284K.

  • 30 institutional investors held Xilio Therapeutics (XLO) as of Q3 2023, down from 32 in Q2 2023.
  • Funds reported $33.5M of Xilio Therapeutics stock for Q3 2023, down 20% quarter-over-quarter.
  • 1 fund opened new Xilio Therapeutics positions in Q3 2023 and 3 closed out, a net change of -2 holders.
  • The largest Xilio Therapeutics buyer in Q3 2023 was Dimensional Fund Advisors, an estimated $22.8K added.
  • The largest Xilio Therapeutics seller in Q3 2023 was Octagon Capital Advisors, an estimated $284K sold.

Based on aggregated 13F filings for Q3 2023.